Merck Makes Pioneering Technologies Gavi, Geri and Gems Available to Fertility Clinics

PR64045

DARMSTADT, Germany, Apr. 11 /PRNewswire=KYODO JBN/--

Not intended for U.S. based media

- Merck obtains CE mark certification for consumables of Gavi(TM) and Geri(TM)

as well as for the embryo culture media suite Gems(TM)

- Geri(TM) now incorporating innovative software module Geri(TM)

- Connect + Assess, allowing fertility labs enhanced control and consistency in

embryo assessment  

All three product families demonstrate Merck's commitment to addressing the

need for high consistency and quality standards in fertility treatment  

Merck, a leading science and technology company today announced that the three

ground-breaking fertility technologies Gavi(TM), Geri(TM) and Gems(TM) are now

available for clinical use in Europe with additional regions to follow in 2016.

Having received CE mark certification for the embryo culture media suite

Gems(TM) as well as for the consumables of Gavi(TM) and Geri(TM), Merck can now

enable customers to fully apply these pioneering technologies and enhance

control and consistency in their assisted reproductive treatment (ART)

processes. For best support within the clinic and enhanced connectivity,

Geri(TM) will be available with the additional software module Geri(TM) Connect

+ Assess which provides clinicians with further help in evaluating the embryo

development potential.

     (Logo: http://photos.prnewswire.com/prnh/20160202/328976LOGO )

     (Photo: http://photos.prnewswire.com/prnh/20160410/353442 )

"Being able to bring Gavi(TM), Geri(TM) and Gems(TM) to market so quickly shows

how Merck is examining every angle of how fertility treatment outcomes can be

improved - from recognizing new technologies to increasing access for patients.

Through our work with clinics, we know that fertility laboratories aim to

increase the success rate in ART through improved control during embryo

development," said Rehan Verjee, Chief Marketing and Strategy Officer at

Merck's biopharma business. "With these needs of physicians and embryologists

in mind, we have aligned our key priorities and are happy to see Gavi(TM),

Geri(TM) and Gems(TM) in full clinical use. These innovative technologies are

just the start of our commitment to further expand our portfolio of practical

solutions to support women and couples in achieving their dream of having a

baby."

All three fertility technologies products were developed to help clinics

improve and facilitate treatment decisions using standardized, automated

protocols and objective information. In particular, the software module

Geri(TM) Connect + Assess represents another step towards a suite of software

solutions that Merck will soon provide with the goal to further drive

innovation in the IVF lab.

Gavi(TM), Geri(TM) and Gems(TM) are commercialized as part of the partnership

between Merck and Genea Biomedx Propriety Limited, Sydney, Australia. Through

Merck's customer and market expertise, the Genea Group's premium fertility

clinics and the world-leading research facility ARTinnovations, the three

technologies benefit from both a deep understanding of the patient experience

and scientific excellence. "We call the convergence of our expertise in

fertility treatment, world leading research and innovation and vigorous

in-house testing, our virtuous circle. This unique combination has led us to

focus on fertility technologies as the real, game-changing solutions to the

challenging issues fertility clinics and people with infertility face," said

Genea CEO Dr Tomas Stojanov.

About Gavi(TM), Geri(TM) and Gems(TM)  

- Gavi(TM) - the world's first fully automated vitrification instrument,

developed with the aim to achieve a consistent and standardized vitrification

process; vitrification is a process used in IVF to preserve human egg cells

(oocytes) or embryos by cooling them to deep sub-zero degrees. Approaching the

process in an innovative way, Gavi(TM) uses an automated, standardized protocol

aiming to provide consistent results in blastocyst vitrification.

- Geri(TM) - a benchtop incubator with individually controlled incubation

chambers per patient to minimize disruptive events to the early-stage embryo.

It also incorporates a time-lapse camera to capture images of embryos as they

develop.

- Gems(TM) - the latest generation of Genea Biomedx's culture media suite for

high-quality embryo cultivation.

Gavi(TM), Geri(TM) and Gems(TM) received the CE mark clearance in Europe, and

also the consumables for Gavi(TM) and Geri(TM) are certified. The three devices

are not yet cleared for use in the USA.

All Merck Press Releases are distributed by e-mail at the same time they become

available on the Merck Website. Please go to

http://www.merckgroup.com/subscribe to register online, change your selection

or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science

and performance materials. Around 50,000 employees work to further develop

technologies that improve and enhance life - from biopharmaceutical therapies

to treat cancer or multiple sclerosis, cutting-edge systems for scientific

research and production, to liquid crystals for smartphones and LCD

televisions. In 2015, Merck generated sales of 12.85 billion Euros in 66

countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical

company. The founding family remains the majority owner of the publicly listed

corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck

name and brand. The only exceptions are the United States and Canada, where the

company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Contact: Bettina Frank, +49-6151-72-4660

SOURCE: Merck KGaA